Source comparison
Head-to-Head Research Comparisons
In rodent resistance exercise models comparing equivalent dosing schedules (IGF-1 LR3 1mg/kg 3×/week vs CJC-1295 2mg/kg 1×/week for equivalent total dose), myofibre CSA increases were comparable at 4-week endpoint in young sedentary animals (both +14-18% gastr
This comparison does not assign a generated winner or score.
- In rodent resistance exercise models comparing equivalent dosing schedules (IGF-1 LR3 1mg/kg 3×/week vs CJC-1295 2mg/kg 1×/week for equivalent total dose), myofibre CSA increases were comparable at 4-week endpoint in young sedentary animals (both +14-18% gastrocnemius CSA, H&E morphometry). However, in aged animals (18-20 month mice), CJC-1295 demonstrated superior satellite cell activation (+28-34% MyoD+ satellite cell density vs +18-22% with IGF-1 LR3), attributed to the concomitant GH → GHR-STAT5b satellite cell stimulation beyond IGF-1 alone. This suggests CJC-1295 may access satellite cell biology through an IGF-1-independent GH axis pathway of greater relevance in aged research contexts where GH secretion has declined.
- In GH-deficient animal models (hypothalamic lesion or hypophysectomy), IGF-1 LR3 fully rescues skeletal muscle protein synthesis (SUnSET +24-30% vs hypophysectomised vehicle), while CJC-1295 has no effect (no pituitary somatotrophs to respond). This confirms that IGF-1 LR3 research applications are appropriate for GH-axis-independent skeletal muscle biology studies, while CJC-1295 requires an intact pituitary for activity.
- In insulin resistance models (HFD-induced), IGF-1 LR3 maintains IGF-1R sensitivity (Akt-Thr308 response preserved even in insulin receptor-desensitised muscle) due to the distinct IRS-1 phosphorylation kinetics of IGF-1R vs insulin receptor. CJC-1295’s efficacy in insulin-resistant models is partially attenuated because hepatic GH resistance (elevated SOCS1/SOCS3) reduces STAT5b-driven IGF-1 synthesis response — a relevant consideration for metabolic syndrome muscle research.